✦ LIBER ✦

Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis

✍ Scribed by Mishra, Jayshree; Drummond, Joseph; Quazi, Sohel H.; Karanki, Satya Sridhar; Shaw, J.J.; Chen, Ben; Kumar, Narendra

Book ID: 119957330
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 880 KB
Volume: 86
Category: Article
ISSN: 1040-8428
DOI: 10.1016/j.critrevonc.2012.09.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combinatorial treatment of non-small-cel

Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy

✍ Luni Emdad; Irina V. Lebedeva; Zao-Zhong Su; Pankaj Gupta; Devanand Sarkar; Jeff 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 497 KB

## Abstract Activation of the epidermal growth factor receptor (EGFR) contributes to the pathogenesis of non‐small‐cell lung carcinomas (NSCLC) and gefitinib, a selective reversible EGFR inhibitor, is effective in treating patients with NSCLC. However, clinical resistance to gefitinib is a frequent

Targeting of tamoxifen to enhance antitu

Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The ‘personalised’ approach?

✍ Hiltrud Brauch; V. Craig Jordan 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 361 KB

Concurrent approaches to combined chemot

Concurrent approaches to combined chemotherapy and chest radiotherapy for the treatment of patients with limited stage small cell lung cancer☆

✍ JOHNSON, B 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 500 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB